NORML

NOVEMBER 25, 2019

Patients suffering from persistent pain conditions who frequently use cannabis are far less likely to use non-prescription opioids, according to longitudinal data published in the journal PLOS One.

Chronic Pain 280

Chronic Pain Patients Therapy Data 280

The Cannigma

NOVEMBER 23, 2021

The app helps patients make sense of their journey by simplifying the information and supplying data-driven insights into their regimen and its effects. We delve into how data can further our understanding of different types of cannabis and why standardization is desperately needed in the industry. Okay, we got to prove it. 0:14:10.3]

Data 52

Data Patients Access Wellness and Beauty 52

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

JANUARY 9, 2019

Then I saw someone with Stage 4 breast cancer end up in remission from cannabis-based therapy, someone else with skin cancer; kid after kid with seizures all being treated. It also gives us a fast-track program. The biggest pushback Phoenix has received until now has been the lack of data, Tindall said.

Therapy 85

Therapy Clinical Trials Treatment Medicine 85

Cannabis Law Report

SEPTEMBER 1, 2022

exas’ leading medical cannabis provider is highlighting the medicine’s efficacy in pain management therapies during Pain Awareness Month. “The data is clear. “Hardly a week goes by without seeing a headline about the staggering amount of fentanyl crossing the border or increase in opioid overdose deaths.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

Cannabis Law Report

OCTOBER 12, 2021

Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a pooled COVID-19 testing program that is grounded in the Company’s EUA-authorized Linea™ COVID-19 Assay Kit. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.

Programs 52

Programs Clinical Trials Research and Development Therapy 52

MMJ Recs

NOVEMBER 17, 2023

Promoting Research and Innovation The medical marijuana industry promotes research and innovation in the field of cannabis-based therapies. Revenue Generation: Maryland’s MMJ program generates revenue for the state, which can be reinvested in public services and healthcare initiatives.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

The Cannigma

AUGUST 5, 2022

2 In 2019 the FDA approved a keta m ine-based nasal spray to treat depression that does not respond to other therapies. Most existing research does not support the use of THC in combating depression and there is very limited data for other cannabinoids.” But this program offers more than just the ketamine itself.

Treatment 138

Treatment Research and Development Therapy Digestion 138

Cannabis Law Report

AUGUST 3, 2021

Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Medxtractor Corp.

Research and Development 105

Research and Development Data Conditions Therapy 105

Cannabis Law Report

AUGUST 31, 2022

Texas’ leading medical cannabis provider is highlighting the medicine’s efficacy in pain management therapies during Pain Awareness Month. The data is clear. In particular, the Baselice & Associates, Inc.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

The Cannigma

FEBRUARY 1, 2023

Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies. Cancer therapy targets the cells that are dividing uncontrollably, while avoiding damage to the non-cancerous cells. How do we currently treat cancer?

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

SpeedWeed

SEPTEMBER 17, 2021

million to assess the efficacy of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI). Wesana is a serious, thoughtful and ethical company engaged in the development of psychedelic-assisted therapy. Lately, MAPS research zeroed in on MDMA-assisted therapy for PTSD.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Veriheal

OCTOBER 20, 2021

Always consult a physician before attempting psychedelic therapy. Data from a nationally representative sample of participants have been collected since 1975 to understand drug use trends among American young adults, and noteworthy findings are published each fall. Cannabis and magic mushrooms for the win! A Magical Future.

Therapy 98

Therapy Microdosing Decriminalization Consumption 98

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.” ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

SpeedWeed

MAY 22, 2021

For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. . This work builds capacity to deliver quality, accessible care to patients, pending approval of MDMA-assisted therapy as a legal prescription treatment.”. View original article.

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

Veriheal

MAY 26, 2022

Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy. Of course, legalization and education efforts can only go so far without data, and that’s where RoC’s research initiatives come into play.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Cannabis Law Report

JUNE 18, 2021

Develop strong partnerships with academic centers, small companies, and translational groups to advance drug discovery projects towards transformative therapies. Minimum of 5 years of relevant industry experience in biotechnology or pharmaceutical companies demonstrating strong data mining and filtering skills. Responsibilities.

Business 104

Business Research and Development Advocacy Data 104

Canna Law Blog

DECEMBER 16, 2021

The bill also provides for the creation a psilocybin services grant program fund for veterans and first responders to be jointly managed by the Commissioner of Health and the state comptroller. The bill allocates $2 million for the grant program. Broad Justification.

Legislation 97

Legislation Treatment Therapy Conditions 97

Cannabis Law Report

SEPTEMBER 23, 2021

This data will assist Awakn’s progress by enabling a better design and more efficient execution of its clinical program. Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (drugs and therapies to be used in combination) to better treat addiction.

Research and Development 52

Research and Development Therapy Treatment Data 52

Cannabis Law Report

MAY 10, 2022

First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. The FDA received MAPS’ protocol for a new study of MDMA-assisted therapy for PTSD.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

DECEMBER 6, 2021

The Company recently presented initial data describing a methodology and findings for the successful determination of Egyptian cotton fiber, yarn and fabric origin using the combination of cotton genomics and isotopic analysis (IA) at an American Apparel and Footwear Association event. Investor Contact: Sanjay M.

Supply Chain 52

Supply Chain Therapy Research and Development Data 52

Cannabis Law Report

OCTOBER 29, 2021

The inclusion of this compound supports and builds upon Mydecine’s strategy to improve the safety and efficacy of its drug development candidates for use in therapy and medical practice. The synthesis of this novel psilocin analogue, a tryptamine, is the newest compound to be added to Mydecine’s growing library of patent-pending compounds.

Pharmaceutical 52

Pharmaceutical Research and Development Data Safety 52

Cannabis Law Report

JUNE 12, 2021

The Parker Psychedelic Research Chair is being funded by Calgary businessman Jim Parker, who donated $3 million to the Hotchkiss Brain Institute to establish the program. “The data was showing that psychedelics were providing benefits to people suffering from anxiety, depression, addiction and PTSD.

Therapy 105

Therapy Treatment Medicine Sleep 105

Cannabis Law Report

JUNE 7, 2021

NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. 1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants 1. P1 (Brazil), and B.1.526

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

SEPTEMBER 2, 2021

– Company’s safeCircle™ Testing Program to Monitor for COVID-19 Among On-Campus Unvaccinated Populations –. Under the Contract, ADCL will deploy safeCircle™, its high-throughput, pooled COVID-19 testing program, to provide cost-effective COVID-19 testing. STONY BROOK, N.Y.–(BUSINESS

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Cannabis Law Report

JULY 20, 2021

While states across the country consider how best to address the mental health and opioid crisis facing our nation, psychedelic medicines are being extensively researched and reported as being a game-changing therapy for PTSD, suicide, chronic pain, and other illnesses. As with any niche industry still in its infancy, the risks are high.

Medicine 98

Medicine Business Research and Development Chronic Pain 98

Cannabis Law Report

DECEMBER 2, 2021

Recommendations and rulemaking relating to training and products were placed on an expedited timeline to ensure that facilitators will be trained, and products will be ready for the January 2, 2023, launch of the first state-sponsored psilocybin therapy program in the United States. Conducting Psilocybin Integration (14 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

MAY 29, 2022

FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. More recently, MDMA therapy has inched closer to FDA approval. 10] In the meantime, FDA has approved some requests for compassionate use. [11].

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JANUARY 31, 2022

This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. “As clinical evidence grows, we look forward to making more treatments available and further advancing the development of psychedelic therapies and mental health innovations.”

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

JULY 27, 2021

If successful, researchers will analyze the data to quantify global gene expression and will use available pipelines to determine differential gene expression between the three lines sampled. The UC Davis scientists will also test new approaches to extract RNA from dried material.

Research and Development 98

Research and Development Pharmaceutical Sativa Extraction 98

TheAnswerPage

JANUARY 11, 2022

As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Who monitors their health and the long-term effects of the marijuana therapy?

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

NOVEMBER 3, 2021

Zerenia™ Clinics UK will build upon Khiron’s presence in the UK which started in 2019 when Khiron became a founding member and also the exclusive Latin American supplier for Project Twenty21 which offers a subsidized pricing model for patients in the program to help address barriers to access in the UK market.

Therapy 52

Therapy Access Patients Treatment 52

Cannabis Law Report

JUNE 30, 2021

s (CSE: MXT) (OTC: MXTTF) SHAMAN and YMI programs apply machine learning to high-resolution health records to better diagnose mental health disorders. Despite the tremendous promise of psychedelics, there are no large-scale standardized clinical trials or data sources that clinicians can use to guide their patient decisions.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Veriheal

APRIL 11, 2022

He also emphasized the fact that medical cannabis programs are now legal in 37 states, as well as four out of five inhabited U.S. I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “We territories.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

JUNE 2, 2021

Aggregate testing results will be reported to the director of the summer camp via safeCircle’s integration with CLEARED4, the Company’s pooled surveillance testing program partner, through CLEARED4’s smartphone-based online health safety management and reporting solution. Testing will be conducted from mid-June through end-July.

Clinical Trials 82

Clinical Trials Therapy Research and Development Collective 82

Cannabis Law Report

NOVEMBER 15, 2021

PCR-produced LinearDNA serves as a pure, fast, and flexible alternative to plasmid DNA (pDNA) in the manufacture of cell and gene therapies (CGTs) and nucleic acid vaccines. CRO orders typically provide a means to evaluate LinearDNA within a customer’s preclinical development program. News release. FDA website. January 15, 2019.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52